

PERSONAL INFORMATION **Violaine Closson Carella**

WORK EXPERIENCE

- June 2016- Present **Cell and Gene Therapy Referent**
ANSM (France)
Regulation of Advanced Therapeutic Medicinal Products at the French regulatory agency (ANSM)
- June 2012-March 2015 **Inspector**
ANSM (France)
Inspection of cell and tissue establishments
- March 2015-May 2016 **Head of Department of Advanced Therapy Medicinal Products/ Organ, Tissue and Cell Preparations**
ANSM (France)
Regulation of medicinal products and Advanced Therapeutic Medicinal Products at the French regulatory agency (ANSM)
- August 2011-January 2012 **Regulatory Affairs Pharmacist**
HRA-Pharma (France)
- June 2007-July 2011 **International Regulatory Affairs Project Manager**
Orphan Europe S.A.R. L. (France)
Management of marketing authorisations of orphan drugs
- December 2001-June 2007 **Cell therapy production manager**
Immuno-Designed Molecules S.A. (France)
Production of cell therapy products for clinical trials
- May 1998-October 2001 **Associate Research Scientist**
Columbia University (United States)
Role of Notch 4 on endothelial cells and angiogenesis
- February 1997-January 1998 **Research Engineer**
INSERM (France)

EDUCATION AND TRAINING

- November 1989-October 1995 **Ph. D in Science: Human Genetics**
University of Paris VII (France)
Expression and function of two ras-related proteins in normal and tumoral human tissue
- November 1989-May 1995 **Ph. D in Specialized Studies of Clinical Pharmacy**
University of Paris V (France)
- October 1983-December 1994 **Ph. D in Pharmacy**
University of Paris V ()

ADDITIONAL INFORMATION

Expertise Cell and gene therapy

- Publications**
- 1-Uyttendaele H, Closson V, Wu G, Roux F, Weinmaster G, Kitajewski J (2000). Notch4 and Jagged-1 induce microvessel differentiation of rat brain endothelial cells. *Microvasc Res* 60(2):91-103.
 - 2-Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T (2000). Notch signaling is essential for vascular morphogenesis in mice. *Genes Dev* 14(11):1343-52.
 - 3-Zalcman G, Closson V, Camonis J, Honore N, Rousseau-Merck MF, Tavitian A, Olofsson B (1996) . RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. *J Biol Chem* 271(48):30366-74.
 - 4-Zalcman G, Closson V, Linares-Cruz G, Lerebours F, Honore N, Tavitian A, Olofsson B (1995) . Regulation of Ras-related RhoB protein expression during the cell cycle. *Oncogene* 18;10(10):1935-45.
 - 5-de Cremoux P, Gauville C, Closson V, Linares G, Calvo F, Tavitian A, Olofsson B (1994). EGF modulation of the ras-related rhoB gene expression in human breast-cancer cell lines. *Int J Cancer* 59(3):408-15.
 - 6-Culine S, Honore N, Closson V, Droz JP, Extra JM, Marty M, Tavitian A, Olofsson B (1994). A small GTP-binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumours. *Eur J Cancer* 30A(5):670-4.
 - 7-Culine S, Honore N, Closson V, Lang P, Bertoglio J, Laroche L, Bussel A, Racadot E, Hovnanian A, Dubertret L, et al (1993). A CD2+ subset of non-malignant peripheral blood lymphocytes from patients with Sezary syndromes overexpress the low-molecular-weight GTP-binding protein Rab2. *Leukemia* 7(4):601-8.
 - 8-Culine S, Honore N, Closson V, Lang P, Bertoglio J, Tavitian A, Olofsson B (1993). A possible role for the Ras-related Rab2 protein in the immunological events associated with hematological malignancies. *Nouv Rev Fr Hematol* 35(1):41-4. Review.

Projects

- Memberships** Member of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA) since 2015

Other Relevant Information